---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-144588"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:01:15.741078+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns

## Summary
- FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.
- Dr. Dominic Smethurst steps down as Chief Medical Officer, effective June 30, 2026.
- Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 (May 29-June 2).
- Company expects to report CRB-701 + Keytruda data in first-line HNSCC in Q4 2026; registrational study for HNSCC to start mid-2026.

## SEC filing metadata
- accession: 0001193125-26-144588
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/0001193125-26-144588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/crbp-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-144588
- JSON: https://secwatch.observer/filing/0001193125-26-144588.json
- Plain text: https://secwatch.observer/filing/0001193125-26-144588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.